Joseph Guydish, PhD, MPH, is Professor of Medicine and Health Policy at the University of California, San Francisco. His research concerns access, delivery, and organization of substance abuse treatment services. He leads the NIDA P50 San Francisco Treatment Research Center, which is focused on continuing and extended models of addiction treatment. He is co-investigator in the regional node of the NIDA Clinical Trials Network, one of 13 such nodes in a national network dedicated to improving substance abuse treatment through multi-site clinical trials research. He has led studies evaluating San Francisco efforts to improve access to publicly-funded drug abuse treatment, assessing federal policy to end drug addiction and alcoholism as an SSI disability category, evaluating needle exchange as an HIV prevention strategy, and investigating Drug Court and intensive case management interventions for drug-involved offenders. He is currently testing strategies designed to support drug abuse treatment programs in better addressing tobacco dependence.
- Discuss the very high prevalence of smoking among persons in addiction treatment, and some of the reasons underlying this high prevalence.
- Explain the role of smoking in excess mortality as well as premature mortality among persons who receive addiction treatment.
- Describe program and policy approaches to better addressing smoking in addiction treatment populations.
- Identify the rate of quit attempts for persons in addiction treatment, and strategies for increasing quit attempts.
- Treatment of Smokers with Co-Occurring Disorders: Emphasis on Integration in Mental Health and Addiction Treatment Settings, by Dr. Sharon Hall and Dr. Jodi Prochaska
- Oregon’s tobacco-free policy for addictions and mental health facilities, a policy example which includes e-cigarettes